LONDON, Oct. 12, 2017 /PRNewswire/ --
• The global market for biological imaging reagents was valued at $13.2 billion in 2016. This market will grow from $14.4 billion in 2017 to nearly $23.9 billion by 2022 with a compound annual growth rate (CAGR) of 10.6% for the period of 2017-2022.
Read the full report: https://www.reportlinker.com/p05142314
• Radioactive imaging as a segment should reach $4.2 billion in 2017 and nearly $8.4 billion by 2022 with a CAGR of 14.7%.
• Optical imaging as a segment should reach $4.9 billion in 2017 and around $7.9 billion by 2022 with a CAGR of 9.8%.
Study Goals and Objectives
BCC Research's goal in conducting this study was to determine the global market and future demand for biological imaging reagents over the five-year period of 2016 through 2022, with a focus on characterizing and quantifying the global market for biological imaging reagents market by technology, reagent type and end user market. We also evaluate future growth opportunities in emerging biological imaging reagents, including quantum dots, nanoparticles, fluorescent proteins and supermolecules. Imaging reagent types covered include fluorescent probes and dyes; fluorescent proteins; nanoparticles; magnetic resonance imaging, ultrasound and X-ray contrast reagents; and imaging radiopharmaceuticals.
Our key objective was to present a comprehensive discussion of where the state-of-the-art is in biological imaging reagents and forecast the future commercial potential for the key market segments. This discussion will provide a basis for companies to make strategic choices about developing new products and markets, or employing biological imaging reagents. The study will benefit reagent and instrument manufacturers, users of biological imaging reagents, medical instrument companies, life sciences tools companies, diagnostic and drug manufacturers, biotechnology companies and developers of nanotechnologies.
Reasons for Doing the Study
Biological imaging reagents play an important role in the medical, pharmaceutical, diagnostic, biotechnology and life sciences tools industries. Imaging and detection technologies are used extensively in medicine, biotechnology and pharmaceutical research. Traditional imaging techniques, such as X-ray, computed tomography (CT), ultrasound (US), magnetic resonance imaging (MRI) and nuclear medicine (NM), mainly analyze anatomy and morphology and cannot detect changes at the molecular level. However, new developments in biotechnology allow us to image at the cellular and molecular level, paving the way for earlier diagnosis and treatment of disease. Biological imaging reagents play a critical role in this medical revolution.
At the same time, ongoing advances in genomics, proteomics and cellular analysis are aided by imaging technologies, including fluorescent dyes and probes, quantum dot nanoparticles and fluorescent proteins. Growth in technologies such as biochips, DNA sequencing and polymerase chain reaction (PCR) relies on sensitive biological fluorescent imaging reagents.
Advances in technologies that are used in biological imaging reagents are also moving forward at a rapid pace. These technologies include nanotechnology, biological targeting, microfluidics, supramolecular chemistry and protein engineering. Rapid developments across a number of technology fields promise to change the biological imaging industry by enabling novel imaging reagents and unique market opportunities. This report analyzes these developments and their impact on the future markets for biological imaging reagents.
Given these market and technology dynamics, it is especially timely to examine the biological imaging reagents market.
Contribution of the Study and for Whom
We have compiled a study of existing and future imaging reagent technologies that will be commercially important in the major end user segments, including life sciences research tools, drug discovery and development and diagnostics.
We present the various imaging reagent technologies, including fluorescent probes and dyes, nanomaterials, fluorescent proteins, contrast reagents and imaging radiopharmaceuticals. We also examine the industry growth driving forces; product types; market applications; companies and industry alliances and acquisitions; future market potential; and product sales forecasts for the period 2017 through 2022. We project the future use of biological imaging reagents in the main end user segments and by technology.
This study will be of particular interest to life sciences research tools suppliers, pharmaceutical manufacturers, diagnostics, biotechnology, genomics, proteomics, nanotechnology and supramolecular companies. It will also be of interest to companies making products for medical imaging, microarrays, lab on a chip, polymerase chain reaction, molecular diagnostics assays, cell-based assays and fluorescence activated cell sorting (FACS) as well as medical researchers and clinicians.
Scope of Report
Topics covered in this report include:
• Fluorescent dyes and probes.
• Fluorescent proteins.
• Nanoparticles, including quantum dots.
• Imaging radiopharmaceuticals.
• Contrast reagents for X-ray/CT, MRI and ultrasound.
Topics not covered in this report include:
• Drug delivery.
• Supramolecular chemistry.
• Imaging instruments and software.
The scope of the study includes the biological imaging reagents that are already commercialized or likely to be commercialized within the next five years. Fluorescent probes and dyes; imaging nanomaterials (including quantum dots and other nanoparticles); fluorescent proteins; contrast reagents for MRI, X-ray and ultrasound; and imaging radiopharmaceuticals are studied. Both the in vivo and in vitro market segments are included. Each technology is analyzed to determine its market status, impact on future market segments and forecast growth from 2017 through 2022. Technology status and market driving forces are also discussed.
BCC Research examines imaging reagent producers and the industry structure in specialized segments of the industry. We also review industry alliances and acquisitions, and the use of biological imaging reagents in key diagnostics and research and development (R&D) tools platforms, including microarrays, lab-on-a-chip devices, DNA sequencing, PCR and cellular analysis. The markets for novel biological imaging reagent applications, including targeted multifunctional and hybrid therapeutic reagents, are analyzed, and the main companies in these fields are highlighted.
Biological Imaging Reagents Market, by Application
- Contrast Imaging
- Optical Imaging
- Radioactive Imaging
Biological Imaging Reagents Market, by Technology
- Small Chemicals
- Chelating Molecules
- Fluorescent Proteins
Biological Imaging Reagents Market, by Modality
Chapter 2: Executive Summary
Biological imaging reagents play a fundamental role in today's medical, pharmaceutical and biotechnology industries. Optical imaging reagents allow life sciences researchers and drug developers to visualize and detect biological processes at the molecular level and to perform key genomics, proteomics and cellular analysis assays. Nuclear and contrast reagents provide important diagnostic information to physicians, enabling the early detection and treatment of disease conditions in cardiology, neurology and oncology.
The strategic importance of biological imaging reagents in life sciences was recognized in 2008 with the awarding of the 2008 Nobel Prize in chemistry to Asamu Shimomura (Japan), Martin Chalfie and Roger Tsien (United States) for their research on green fluorescent proteins (GFPs). GFPs are an important class of biological imaging reagents that are widely used in proteomics and cellular analysis. The global market for biological imaging reagents is primarily driven by advancements in biomarker technology in medical diagnostics. Biomarkers have tremendous potential to impact the success rates of clinical trials, drug development and medical diagnosis.
However, lack of standardization has always been a major challenge in biomarker diagnosis. Moreover, in working toward establishing interoperability among clinical systems, the demand for automated image quantification and integration of clinical and image data has emerged. Thus, the continuous developments in quantitative imaging biomarkers (QIBs) had created the need for standards as the images acquired are not uniform and there can be differences in interpretation at different levels. Image-based assessment of treatment responses can be highly variable, depending on the make and model of the imaging equipment used and how the images were acquired, processed and the guidelines by which they were interpreted.
For example, if a cancer patient has a positron emission tomography (PET) scan done at one hospital using one type of scanner and procedures, and two months after treatment has a PET scan on a different scanner or with different procedures, the measurements from the two scans might not be comparable. To address this issue, the Radiological Society of North America has established the Quantitative Imaging Biomarker Alliance (QIBA), which aims to improve the value and practicality of quantitative imaging biomarkers by reducing variability across devices and time. Currently, QIBA standards have been established for two standardized profiles, which include accurate and reproducible 18Ffluorodeoxyglucose (FDG) PET/CT measurements; and CT tumor volume measurements.
This will improve the reliability of cancer imaging studies and is considered a major positive trend in the global market for biological imaging reagents. The global biological imaging market is expected to reach nearly $23.9 billion by 2022 at a compound annual growth rate (CAGR) of 10.6% during the forecast period of 2017 to 2022.
Imaging reagents consist of a diverse class of technologies. Fluorescent probes and dyes cover a significant part of the imaging reagents industry. Furthermore, fluorescent proteins; nanoparticles; fullerene and dendrimer supermolecules; magnetic resonance imaging; ultrasound and X-ray contrast reagents; and imaging radiopharmaceuticals are also important reagents.
Biological imaging reagents are integral to the diagnostics industry, which is the largest market for these products. Selective, targeted imaging reagents show promise for new medical diagnostic applications, including the early detection of Alzheimer's disease and cancers. The use of semiconductor quantum dots has become very popular in bioimaging since the early 2000s. However, in the coming years the industry is expected to witness tremendous developments in carbon nanomaterials and nuclear imaging techniques. Various types of other nanoparticles are also under investigation, including solid lipid nanoparticles, liposomes, micelles, nanotubes, metallic nanoparticles, dendrimers, polymeric nanoparticles and iodinated nanoparticles.
The main biological imaging reagent classes, shown in the Summary Table below, include contrast, nuclear and optical. Contrast reagents include magnetic resonance imaging (MRI), ultrasound and Xray/ CT. Nuclear reagents include imaging radiopharmaceuticals. Optical reagents include fluorescent dyes and probes, gold nanoparticles, quantum dots (QDs) and fluorescent proteins.
Read the full report: https://www.reportlinker.com/p05142314
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: email@example.com
Intl: +1 339-368-6001